David is dedicated to improving the lives of people affected by CNS diseases, combining this mission with his proven ability to build high-value companies. As CEO of Psy Therapeutics, he leads a high-performance team advancing an innovative pipeline and forging key scientific partnerships. David served as Chairman of the Board of McLean Hospital, an affiliate of Harvard Medical School, from 2008 to 2018, during which McLean was ranked the #1 psychiatric hospital in the U.S. and strengthened its leadership in clinical care, research, and education. With 40 years in biopharma, David has built and led companies at all stages. As Chairman & CEO of Molecular Insight Pharmaceuticals, he guided the company from early-stage development to a public leader in novel radiotherapeutics and molecular imaging radiopharmaceuticals. As President of Pharmaceuticals at Sepracor (now Sunovion), he grew the organization from a small scientific team into a fully integrated commercial enterprise. David has served on multiple biopharma and nonprofit boards and is an Honorary Trustee of McLean Hospital and an Honorary member of the President’s Council at MGH. He is also on Vanderbilt University’s Advisory Council for Technology Transfer. He holds a BA from Bates College and an MBA from Stanford University.